Skip Navigation


QJM Advance Access originally published online on April 4, 2006
QJM 2006 99(5):307-315; doi:10.1093/qjmed/hcl038
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
99/5/307    most recent
hcl038v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Baughman, R.P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baughman, R.P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oxfordjournals.org

Presenting characteristics as predictors of duration of treatment in sarcoidosis

R.P. Baughman1,, M.A. Judson2, A. Teirstein3, H. Yeager4, M. Rossman5, G.L. Knatterud6, B. Thompson6 for the ACCESS research team

From the 1University of Cincinnati Medical Center, Cincinnati, Ohio, 2Medical University of South Carolina, Charleston, South Carolina, 3Mount Sinai Medical Center, New York, New York, 4Georgetown University Medical Center, Washington DC, 5University of Pennsylvania and MCP-Hahnemann University Medical Centers, Philadelphia, Pennsylvania, and 6Clinical Trials and Surveys Corporation, Baltimore, Maryland, USA

Address correspondence to Dr R.P. Baughman, 1001 Holmes, Eden Ave, Cincinnati, OH 45267–0565, USA. email: bob.baughman{at}uc.edu

Received 29 July 2005 and in revised form 8 March 2006

Background: Some sarcoidosis patients never need therapy, but many still require therapy more than 2 years after initial diagnosis.

Aim: To determine what features at initial presentation are associated with treatment 2 years later.

Methods: Patients with biopsy-confirmed sarcoidosis enrolled in the ACCESS (A Case Control Etiologic Study of Sarcoidosis) study were initially evaluated within 6 months of diagnosis. Pulmonary function, chest X-ray and dyspnoea score were measured, and systemic therapy for the sarcoidosis recorded. Organ involvement was assessed using a standardized instrument. A subset (n = 215) were seen 18–24 months later for follow-up, and these patients constitute our study group.

Results: Ten patients had only received therapy before the first visit, with no further therapy, and were excluded from analysis. Of the remaining 205, 95 were not on therapy at the initial visit and 75 (79%) of these were never treated during follow-up. Of the 110 initially on therapy, 52 (47%) remained on therapy at follow-up. Other initial features associated with continued therapy were the level of dyspnoea and predicted vital capacity. On logistic regression, only dyspnoea and therapy at initial visit remained significant. Patients on systemic therapy at initial evaluation were more likely to be on therapy at follow-up (OR 3.6, p = 0.003). Neither ethnicity nor gender independently predicted therapy at follow-up.

Discussion: This study group represents a sample of newly diagnosed sarcoidosis patients. However, this is a referral population, and there was no set protocol for treatment. Use of systemic therapy within the first 6 months after diagnosis appears to be strongly associated with continued use of therapy 2 years later.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JAMAHome page
S. E. Weinberger
A 47-year-old woman with sarcoidosis.
JAMA, November 1, 2006; 296(17): 2133 - 2140.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.